Cellebrite DI (NASDAQ:CLBT – Free Report) had its target price upped by Craig Hallum from $14.00 to $16.00 in a report released on Monday, Benzinga reports. The firm currently has a buy rating on the stock. Several other research analysts have also recently commented on CLBT. Needham & Company LLC upped their target price on […]